Technical Research on Biotech Equities -- Celsion, Sarepta Therapeutics, BioMarin Pharma, and ContraVir Pharma

Friday, June 23, 2017 Drug News
Email Print This Page Comment bookmark
Font : A-A+

NEW YORK, June 23, 2017 /PRNewswire/ --

If you want a Stock Review on CLSN, SRPT, BMRN or CTRV then come over to and sign up for your free customized report today. For today, has issued research reports on Celsion Corp. (NASDAQ: CLSN), Sarepta Therapeutics Inc. (NASDAQ: SRPT), BioMarin Pharmaceutical
Inc. (NASDAQ: BMRN), and ContraVir Pharmaceuticals Inc. (NASDAQ: CTRV). According to an article on Seeking Alpha, it views Biotech companies as potential drivers of above-average, long-term earnings growth, whose multiples have been compressed by increased scrutiny of drug pricing. Despite recent weakness, three of the four trends that powered the biopharmaceutical bull market from 2011 to 2015 remain in place today. Take a look at the free research reports issued today on for these stocks by signing up at:


On Thursday, shares in Lawrenceville, New Jersey headquartered Celsion Corp. recorded a trading volume of 3.11 million shares, which was higher than their three months average volume of 730,850 shares. The stock ended the day at $2.63, surging 8.68% from the last trading session. The Company's shares are trading below their 50-day moving average by 20.77%. Furthermore, shares of Celsion, which focuses on the development and commercialization of directed chemotherapy, DNA-mediated immunotherapy, and RNA based therapy products for the treatment of cancer, have a Relative Strength Index (RSI) of 45.83.

On June 19th, 2017, Celsion announced that it has entered into definitive agreements with several institutional investors to purchase an aggregate of approximately $5.4 million of shares of common stock, or pre-funded warrants in lieu thereof, in a registered direct offering. The Company agreed to sell an aggregate of approximately 2 million shares of common stock, or pre-funded warrants in lieu thereof, at a price of $2.75 per common share or warrant share, respectively, in the registered direct offering. Sign up and read the free research report on CLSN at:

Sarepta Therapeutics 

Cambridge, Massachusetts headquartered Sarepta Therapeutics Inc.'s stock climbed 0.31%, finishing yesterday's session at $35.48. A total volume of 2.32 million shares was traded, which was above their three months average volume of 1.86 million shares. The Company's shares have gained 9.95% in the last month, 19.54% over the previous three months, and 29.35% since the start of this year. The stock is trading above its 50-day moving average by 8.33%. Additionally, shares of Sarepta Therapeutics, which focuses on the discovery and development of RNA-based therapeutics for the treatment of rare neuromuscular diseases, have an RSI of 64.63.

On June 21st, 2017, Sarepta Therapeutics and Genethon, a non-profit R&D organization dedicated to the development of biotherapies for orphan genetic diseases from research to clinical validation, have signed a gene therapy research collaboration to jointly develop treatments for Duchenne muscular dystrophy (DMD). Genethon's micro-dystrophin gene therapy approach can target the majority of patients with DMD. It has demonstrated proof-of-concept of its micro-dystrophin program via robust gene expression in a large animal model of DMD. The complimentary research report on SRPT can be downloaded at:

BioMarin Pharma 

Shares in San Rafael, California headquartered BioMarin Pharmaceutical Inc. ended the session 1.78% lower at $97.06. The stock recorded a trading volume of 1.84 million shares, which was above its three months average volume of 1.15 million shares. The Company's shares have gained 9.85% in the last one month, 11.77% over the previous three months, and 17.17% on an YTD basis. The stock is trading 6.40% above its 50-day moving average and 8.81% above its 200-day moving average. Moreover, shares of BioMarin Pharma, which develops and commercializes pharmaceuticals for serious diseases and medical conditions in the US, Europe, Latin America, and internationally, have an RSI of 62.79.

On June 16th, 2017, BioMarin Pharma announced that it will present data in a late-breaking abstract session at the International Society on Thrombosis and Haemostasis 2017 Congress to be held from July 08th, 2017 to July 13th, 2017 in Berlin, Germany. The presentation will report interim results from a Phase-1/2 study of BMN 270, an AAV5-FVIII Gene transfer in severe hemophilia. Register for free on and access the latest report on BMRN at:

ContraVir Pharma 

At the closing bell on Thursday, Edison, New Jersey headquartered ContraVir Pharmaceuticals Inc.'s stock declined 0.02%, finishing at $0.63. A total volume of 702,117 shares was traded. The Company's shares are trading 23.82% below their 50-day moving average. Additionally, shares of ContraVir Pharma, which operates as a biopharmaceutical company focused on the development of antiviral drugs with a primary emphasis on the treatment of Hepatitis B virus (HBV) infections, have an RSI of 42.20. Get free access to your research report on CTRV at:


Daily Stock Tracker: 

Daily Stock Tracker (DST) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. DST has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below. 

DST has not been compensated; directly or indirectly; for producing or publishing this document. 


The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by DST. DST is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.  


DST, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. DST, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, DST, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice. 


This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither DST nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit

CONTACT For any questions, inquiries, or comments reach out to us directly. If you're a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at: Email: Phone number: (207)331-3313 Office Address: 377 Rivonia Boulevard, Rivonia, South Africa

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE Chelmsford Park SA

Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions

News A - Z


News Search

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Find a Doctor

Press Release Category

Press Release Archive

Stay Connected

  • Available on the Android Market
  • Available on the App Store